Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Apr 17 2018

• By Emily Hayes

Instagram style filter silhouette of a successful woman or girl arms raised celebrating at sunrise or sunset in front of the New York City Skyline

Related Content

Bristol's Opdivo/Yervoy Bid Will Show Whether Tumor Mutation Burden Is Ready For Prime Time

Feb 06 2018

Does CheckMate 026 Take Bristol Out Of The End Game?

Aug 06 2016

Merck's Keytruda Claims Market Leadership In First-line Lung Cancer

Jul 30 2017

Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

Nov 14 2017

Merck Hits IO Bullseye With Keytruda Combo In First-line Lung Cancer

Jan 17 2018

Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy

Apr 10 2018

Buoyed By US Tax Reform, Merck Plans $12bn In Capital Investments

Feb 02 2018

Bristol Debuts Opdivo/Yervoy Data In New First-Line Lung Cancer Bid

Feb 06 2018

Related Companies

Merck & Co., Inc.

Bristol Myers Squibb Company

Eli Lilly and Company

Pfizer Inc.

Foundation Medicine, Inc.

Additional Topics

ImmunoOncology Market Intelligence Clinical Trials Business Strategies Research & Development Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window